Interim 2017 results and business update
(WorldNews France)

Interim 2017 results and business update Ramp-up of industrial capacity underway, with some adjustments to ensure GMP compliance Impacts on the provisional schedule: delay of approximately 6 months for priority US filings Confirmation of the aim of negotiating licensing agreements in 2017 Reinforcement in emergency products: introduction of Zeneo® Terbutaline (acute asthma attack) into the portfolio Cash position as of end-June 2017: EUR6.1 million, as expected; further contributions of EUR5.9 million are anticipated by the end of 2018 (excluding commercial upfronts) Dijon, 21 September 2017 CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of...